Department of Urology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Neoplasma. 2019 Nov;66(6):1019-1023. doi: 10.4149/neo_2019_190124N74. Epub 2019 Oct 8.
Aim of the study is to define the diagnostic accuracy of selected urinary protein biomarkers in the non-invasive detection of primary and recurrent urothelial carcinoma of the urinary bladder. The urinary levels of calprotectin, CD147, APOA4 and protein deglycase DJ-1 were examined in 255 individuals, including 60 controls with non-malignant urological disease, 61 patients with a history of urinary bladder cancer with negative cytology and negative cystoscopy and 134 patients with urinary bladder cancer. Urinary concentrations of biomarkers were determined by Enzyme-Linked Immunosorbent Assay (ELISA). During the follow-up of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared to the group of 61 patients with a history of NMIBC but with no evidence of disease. Urinary concentrations of the evaluated markers did not reveal any significant difference between these groups. During the primary diagnosis, a group of 90 patients with primary bladder cancer and 60 subjects with benign disease were compared. Urinary levels of CD147 were not significantly higher in patients with tumors. The greatest diagnostic accuracy was observed in APOA4 (sensitivity 55.6, specificity 83.3, AUC 0.75), and lesser in calprotectin (sensitivity 39.4, specificity 87.7, AUC 0.66) and in DJ-1 (sensitivity 61.1, specificity 66.7, AUC 0.64), respectively. Apolipoprotein A4 may be used potentially as a supplemental urinary marker in the diagnosis of primary bladder cancer.
本研究旨在确定选定的尿蛋白生物标志物在非侵入性检测原发性和复发性尿路上皮膀胱癌中的诊断准确性。在 255 名个体中检查了钙卫蛋白、CD147、APOA4 和蛋白去糖基酶 DJ-1 的尿水平，包括 60 名非恶性泌尿系统疾病的对照者、61 名膀胱癌病史且细胞学和膀胱镜检查均为阴性的患者和 134 名膀胱癌患者。通过酶联免疫吸附测定（ELISA）测定生物标志物的尿浓度。在非肌肉浸润性膀胱癌（NMIBC）患者的随访期间，将一组 44 名癌症复发患者与一组 61 名有 NMIBC 病史但无疾病证据的患者进行比较。这些组之间评估标志物的尿浓度没有显示出任何显着差异。在原发性诊断期间，将一组 90 名原发性膀胱癌患者和 60 名良性疾病患者进行了比较。肿瘤患者的尿 CD147 水平没有显着升高。APOA4 的诊断准确性最高（敏感性 55.6%，特异性 83.3%，AUC 0.75），而钙卫蛋白（敏感性 39.4%，特异性 87.7%，AUC 0.66）和 DJ-1（敏感性 61.1%，特异性 66.7%，AUC 0.64）的诊断准确性较低。载脂蛋白 A4 可能可作为原发性膀胱癌诊断的辅助尿标志物。
